Special Report: KRAS Finding Changes Oncology Practice But Poses Profound Regulatory Dilemma
FDA Concerned About Data-Dredging In Drug-Diagnostic Applications
Government Offers Two Approval Standards For Assays: CLIA, FDA
FDA Ponders Standards For “Retrospective Prospective” Studies
ODAC Discussion: NCI’s Richard Simon Cautions About Rules Of Thumb
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- No need for a speculum? A new era of HPV screening
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally









